Dynamic kinetic asymmetric transformation in copper catalyzed allylic alkylation

Jean-Baptiste Langlois and Alexandre Alexakis*^[a]

^[a]University of Geneva. Department of Organic Chemistry. Quai E. Ansermet, 30. CH-1211 Geneva 4 (Switzerland)

Alexandre.alexakis@unige.ch

Supporting Information

- I) General remarks
- **II)** Additional datas
- **III)** General procedure
- IV) References
- V) Spectroscopic datas

I) General remarks

All reactions were carried out under argon atmosphere with flame-dried glassware. Solvents were dried by filtration over alumina previously activated at 350°C during 12 hours under nitrogen before use. ¹H (400 MHz) and ¹³C (100 MHz) NMR spectra were recorded on a Bruker 400FTNMR in CDCl₃, and chemical shift (δ) are given in ppm relative to residual CHCl₃. Multiplicity is indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (doublet of doublet), dt (doublet of triplet), ddd (doublet of doublet of doublet), qd (quartet of doublet), brs (broad singlet). Coupling constants are reported in Hertz (Hz). Evolution of reaction was followed by GC-MS (EI mode) on an HP6890. Optical rotations were recorded on a Perkin-Elmer 241 polarimeter at 25°C in a 10 cm cell in the stated solvent; [α]_D values are given in 10⁻¹ deg.cm² g⁻¹ (concentration c given as g/100 mL). Enantiomeric excesses were determined by chiral GC measurement either on a HP6890 (H₂ as vector gas) or HP6850 (H₂ as vector gas) with the stated column. Temperature programs are described as follows: initial temperature (°C) - initial time (min) - temperature gradient (°C/min) - final temperature (°C); retention times (R_T) are given in min. Enantiomeric excesses were in some cases determined by chiral-SFC measurement on a Berger SFC with the stated column. Gradient programs are described as follows: initial methanol concentration (%) - initial time (min) - percent gradient of methanol (%/min) - final methanol concentration (%); retention times (R_T) are given in min. Flash chromatography was performed using silicagel 32-63 µm, 60 Å.

All chiral ligands were prepared according to the litterature procedure (for ligands **L1-L6**, see reference 1, for ligand **L7**, see reference 2, ligand **L8** was a gift from Solvias, for ligand **L9**, see reference 3). CuTC was purchased from FrontierScientific and used as received.

Substrates were prepared according to the literature (for substrate 5, 8 and 9 see reference 4, for substrate 10, see references 5 and 6). Substrate 8 is very light and air sensitive so it is used directly after its distillation. Epoxides were prepared according to the literature (see reference 7).

II) Additional datas

Table 1. Influenc	e of the nature	of the c	copper s	ource ^[a]
-------------------	-----------------	----------	----------	----------------------

Entry	Cu salt	Conversion [%] ^[b]	ee [%] ^[c]
1	CuTC	>99	86 (S)
2	CuBr.SMe2	>99	80 (<i>S</i>)
3	CuBr	>99	82 (<i>S</i>)
4	CuCl	>99	82 (<i>S</i>)
5	Cu(OAc) ₂	>99	82 (S)
6	Cu(OTf) ₂	>99	56 (<i>S</i>)
7	CuCN	>99	28 (S)

[a] Reaction conditions: Racemic substrate **5** (0.5 mmol) was added to a solution of Cu salt (5 mol%) and **L1** (5.5 mol%) in dry DCM (4 ml). Reaction mixture was cooled to - 78°C and Grignard reagent (1 M in Et₂O, 1.5 equiv) was added dropwise.[b] Conversion determined by GC-MS.[c] Determined by GC on a chiral stationary phase.



Figure 1. Enantiomeric excess of the product 7 as a function of the conversion of the reaction.



[a] Reaction conditions: Organometallic reagent (1.2 eq) was added dropwise, at -78°C, to a solution containing the substrate, the Cu salt and the ligand. [b] Yield of isolated product. [c] Organozinc reagent was prepared by addition of two equivalents of Grignard reagent to $ZnBr_2$ in DCM. [d] Determined by GC on a chiral stationary phase after derivatisation of a sample of the isolated product into the corresponding epoxides.

III) General procedure for copper catalyzed asymmetric allylic alkylation

In a flame-dried Schlenk tube under argon atmosphere, CuTC (7.2 mg, 0.038 mmol, 0.075 eq) and L1 (22.2 mg, 0.041 mmol, 0.083 eq) were dissolved in dry DCM (4 ml) and the solution was stirred for 10 min at room temperature. Then the substrate (0.5 mmol) was added and the solution was cooled to -78° C. After 10 min at this temperature, the alkylmagnesium bromide

solution 1M in Et_2O (0.6 ml, 0.6 mmol, 1.2 eq) was added dropwise and the reaction mixture was stirred for 1h. The reaction was quenched with a aqueous solution of HCl 1M (15 ml) and extracted with Et_2O (15 ml). Organic layer was washed with HCl 1M (15 ml) and brine (15 ml), dried over Na_2SO_4 , filtered and concentrated on vacuo. Crude mixture was purified on silica gel chromatography column (pentane). Desired product was recovered as a colorless liquid. A sample of the isolated product was treated with *m*cpba and Na_2HPO_4 in DCM. After 1h, Et_2O (10 ml) was added and the reaction was quenched with an aqueous solution of saturated $Na_2S_2O_3$. Organic layer was washed two times with an aqueous solution of NaOH 1M, dried over Na_2SO_4 , filtered and concentrated on vacuo. The crude mixture of two diastereoisomeric epoxides was directly analyzed in chiral GC.



(*S*)-(2-(cyclohex-2-enyl)ethyl)benzene 7: prepared from cyclohex-1-enyl-3-bromide 5. Yield = 95 %. The enantiomeric excess was determined by GC on a chiral stationary phase (Hydrodex B3P column, Method: 60-30-1-140-20-170-5, R_T: 102.17 (*S*), 102.76 (*R*) min). The enantiomeric excess was also determined after derivatisation in corresponding epoxides (Hydrodex TBDM column, Method: 60-01-170-5, R_T: 97.99, 99.01, 102.71, 104.25 min). $[\alpha]^{25}{}_{\rm D}$ = -104.4 (c = 1.2 in CHCl₃, 92 % ee). ¹H NMR (400 MHZ, CDCl₃, 25°C): δ = 1.34-1.37 (m, 1H), 1.59-1.81 (m, 4H, 1.89 (m, 1H), 2.06 (m, 2H), 2.18 (m, 1H), 2.74 (m, 2H), 5.71-5.76 (m, 2H), 7.25-7.35 ppm (m, 5H); ¹³C NMR (100 MHZ, CDCl₃, 25°C): δ = 21.6, 25.5,

29.2, 33.4, 34.9, 38.4, 125.8, 127.3, 128.4, 128.5, 131.9, 143 ppm. IR (CHCl₃): 71.9, 1453, 1493, 2856, 2923, 3023 cm⁻¹. MS (EI mode) m/z %: 186 (28), 143 (4), 129 (4), 104 (26), 91 (100), 65 (34), 53 (22). HRMS (ESI) calcd for C₁₄H₁₈ [M⁺] 186.1407, found 186.1409.



(*S*)-3-(4-tert-butoxybutyl)cyclohex-1-ene 13: prepared from cyclohex-1-enyl-3-bromide 5. Yield = 91 %. The enantiomeric excess was determined by GC on a chiral stationary phase after derivatisation in corresponding epoxides (Hydrodex TBDM column, Method: 60-0-1-170-5, R_T : 87.43, 88.95, 91.50, 93.15 min). [α]²⁵_D = -145.8 (c = 1.8 in CHCl₃, 90 % ee). ¹H NMR (400 MHZ, CDCl₃, 25°C): δ = 1.17 (s, 9H), 1.35-1.37 (m, 5H), 1.49 (m, 2H), 1.94-2.03 (m, 3H), 3.32 (t, 2H, J = 6.6 Hz), 5.57-5.63 ppm (m, 2H); ¹³C NMR (100 MHZ, CDCl₃, 25°C): δ = 21.6, 23.7, 25.5, 27.7, 29.2, 31, 35.3, 36.4, 61.7, 72.5, 126.8, 132.4 ppm. IR (CHCl₃): 1083.7, 1198.7, 1361.6, 2860.9, 2929.4, 2973.2 cm⁻¹. MS (EI mode) *m*/z %: 226 (8), 207 (10), 163 (2), 147 (2), 135 (12), 93 (8), 71 (12), 57 (100). HRMS (ESI) calcd for corresponding epoxide C₁₄H₂₆O₂ [M⁺] 226.1933, found 226.1927.



(*S*)-3-cyclohexylcyclohex-1-ene 14: prepared from cyclohex-1-enyl-3-bromide 5.Yield = 98 %. The enantiomeric excess was determined by GC on a chiral stationary phase after derivatisation in corresponding epoxides (Hydrodex TBDM column, Method: 60-0-1-170-5, R_T : 71.96, 72.42, 79.05, 80.11 min). $[\alpha]^{25}_D$ = -42 (c = 1.0 in CHCl₃, 70 % ee). ¹H NMR (400 MHZ, CDCl₃, 25°C): δ = 1.02-1.34 (m, 7H), 1.49 (m, 1H), 1.72 (m, 7H), 1.94 (m, 3H), 5.62-5.67 ppm (m, 2H). ¹³C NMR (100 MHZ, CDCl₃, 25°C): δ = 22.4, 25.6, 25.9, 26.9, 30, 30.4, 41.1, 42.8, 127.3, 131.2 ppm. IR (CHCl₃): 721.2, 1448, 2851.8, 2933.3, 3022.9 cm⁻¹. MS (EI mode) *m*/z %: 164 (30), 149 (4), 135 (6), 121 (6), 97 (8), 82 (100), 81 (65), 55 (90), 53 (26). HRMS (ESI) calcd for C₁₂H₂₀ [M⁺] 164.1564, found 164.1565.



Cyclohex-2-enylbenzene 16: prepared from **cyclohex-1-enyl-3-bromide 5**.Yield = 97 %. The enantiomeric excess was determined by SFC on a chiral stationary phase after derivatisation in corresponding epoxides (Chiracel OJ column, Method: MeOH 2%-2-1-15%, R_T : 4.57 (*S*), 4.97 (*R*) min). ¹H NMR (400 MHZ, CDCl₃, 25°C): $\delta = 1.51$ (m, 2H), 1.69 (m, 1H), 1.96-2.04 (m, 3H), 3.35 (m, 1H), 5.68 (m, 1H), 5.82 (m, 1H), 7.14-7.25 ppm (m, 5H). ¹³C NMR (100 MHZ, CDCl₃, 25°C): $\delta = 21.3$, 25.2, 32.8, 42, 126.1, 127.9, 128.4, 128.5, 130.3, 146.8 ppm. IR (CHCl₃): 701, 723.6, 755.2, 1075.2, 1451.6, 1491.6, 1738.9, 2836.6, 2931.5, 3022.9 cm⁻¹. MS (EI mode) *m*/z %: 158 (100), 143 (52), 129 (92), 115 (66), 104 (20), 77 (30), 65 (18), 63 (14), 51 (32). HRMS (ESI) calcd for C₁₂H₁₄ [M⁺] 158.1095, found 158.1096.



(*S*)-(2-(cyclopent-2-enyl)ethyl)benzene 17: prepared from cyclopent-1-enyl-3-bromide 8 directly after its distillation. Yield = 93 %. The enantiomeric excess was determined by GC on a chiral stationary phase after derivatisation in corresponding epoxides (Hydrodex TBDM column, Method: 60-0-1-170-5, R_T: 86.75, 87.23, 94.06, 95.54 min). $[\alpha]^{25}_{D} = -117$ (c = 1.5 in CHCl₃, 44 % ee). ¹H NMR (400 MHZ, CDCl₃, 25°C): $\delta = 1.51$ (m, 3H), 2.14 (m, 1H), 2.37 (m, 2H), 2.71 (m, 3H), 5.76 (m, 2H), 7.22-7.32 ppm (m, 5H). ¹³C NMR (100 MHZ, CDCl₃, 25°C): $\delta = 29.9$, 32.1, 34.4, 45.3, 125.7, 128.4, 128.5, 130.6, 135, 142.9

ppm. IR (CHCl₃): 697.7, 717.5, 748.6, 772.2, 1362.2, 1454.2, 1496, 1739.1, 2850.5, 2929.9, 30.26.9, 3050.9 cm⁻¹. MS (EI mode) m/z %: 172 (28), 152 (2), 144 (8), 129 (4), 115 (4), 104 (36), 92 (88), 81 (44), 67 (100), 53 (14), 51 (18). HRMS (ESI) calcd for C₁₃H₁₆ [M⁺] 172.1249, found 172.1252.



(S)-(2-(cyclohept-2-enyl)ethyl)benzene 18: prepared from cyclohept-1-enyl-3-bromide 9. Yield = 98 %. The enantiomeric excess was determined by GC on a chiral stationary phase after derivatisation in corresponding epoxides (Hydrodex TBDM column, Method: 60-0-1-170-5, R_T: 107.43, 109.05, 109.87, 110.70 min). $[\alpha]_{D}^{25} = -18$ (c = 1.0 in CHCl₃, 38 % ee). ¹H NMR (400 MHZ, CDCl₃, 25°C): $\delta = 1.25$ (m, 2H), 1.32-1.35 (m, 5H), 1.95 (m, 1H), 2.15 (m, 2H), 2.26 (m, 1H), 2.65 (m, 2H), 5.67 (m, 1H), 5.80 (m, 1H), 7.19-7.29 ppm (m, 5H). ¹³C NMR (100 MHZ, CDCl₃, 25°C): $\delta = 27.1$, 28.9, 30.7, 33.5, 33.8, 39, 39.3, 125.7, 128.4, 128.5, 131.6, 137.8, 143 ppm. IR (CHCl₃): 697.6, 747.7, 1217.2, 1365.9, 1453.5, 1496.2, 1738.2, 2850.1, 2933.3, 3024.7 cm⁻¹. MS (EI mode) *m*/z %: 200 (14), 172 (2), 143 (6), 129 (4), 104 (32), 91

(100), 67 (62), 55 (30). HRMS (ESI) calcd for $C_{15}H_{20}$ [M⁺] 200.1565, found 200.1565.



(S)-(2-(2-methylcyclohex-2-enyl)ethyl)benzene 19: prepared from 1-methylcyclohex-1-enyl-6-bromide 10. Yield = 95 %. The enantiomeric excess was determined by GC on a chiral stationary phase after derivatisation in corresponding epoxides (Hydrodex TBDM column, Method: 60-0-1-170-5, R_T : 93.90, 96.29, 98.94, 100.37 min). [α]²⁵_D = -7.5 (c = 1.25 in CHCl₃, 18 % ee). ¹H NMR (400 MHZ, CDCl₃, 25°C): $\delta = 1.56 - 1.70 \text{ (m, 5H)}, 1.68 \text{ (s, 3H)}, 1.99 \text{ (m, 4H)}, 2.55 - 2.75 \text{ (m, 2H)}, 5.45 \text{ (s, 1H)}, 7.23 - 7.31 \text{ ppm (m, 5H)}.$ ¹³C NMR (100 MHZ, CDCl₃, 25°C): δ = 19.9, 22.3, 25.7, 27.5, 33.7, 34.7, 38.4, 122.8, 125.7, 128.4, 128.5, 137.1, 143.1 ppm. IR (CHCl₃): 697.9, 748.2, 1217.1, 1377.1, 1453.5, 1496.1, 1739.2, 2858.3,

2929.8, 3026.3). MS (EI mode) *m*/z %:. HRMS (ESI) calcd for C₁₅H₂₀ [M⁺] 200.1565, found 200.1566.



(R)-3-ethylcyclohex-1-ene 11: prepared from cyclohex-1-enyl-3-bromide 5. Highly volatile product isolated after derivatisation in corresponding epoxides. After treatment with mcpba, 2-ethyl-7-oxabicyclo[4.1.0]heptane is isolated as a mixture of diastereoisomeric epoxides with a ratio 1/1. Yield = 79 % (after two steps). ¹H NMR (400 MHZ, CDCl₃, 25°C): $\delta = 0.82$ (m, 1H), 0.98 (m, 6H), 1.22 (m, 2H), 1.36-1.83 (m, 13H), 2.05 (m, 2H), 2.85 (m, 1H), 3.12 ppm (m, 3H). 13 C NMR (100 MHZ, CDCl₃, 25°C): $\delta = 11.8, 17.4,$ 20.2, 24.1, 25, 26.3, 27, 27.1, 36.1, 36.9, 52.9, 55.7, 56.4 ppm. IR (CHCl₃): 1217, 1259.9, 1364.8, 1419, 1738.1, 2936.6 cm⁻¹. MS (EI mode) m/z %: 126 (8), 111 (30), 97 (56), 82 (42), 67 (100), 55 (96), 51 (10).

HRMS (ESI) calcd for C₈H₁₄O [M⁺] 126.1044, found 126.1045.



(R)-3-butylcyclohex-1-ene 12: prepared from cyclohex-1-enyl-3-bromide 5. Highly volatile product isolated after derivatisation in corresponding epoxides. After treatment with mcpba, 2-butyl-7-oxabicyclo[4.1.0]heptane is isolated as a mixture of diastereoisomeric epoxides with a ratio 1/1. Yield = 81 % (after two steps). ¹H NMR (400 MHZ, CDCl₃, 25°C): $\delta = 0.81$ (m, 1H), 0.89 (m, 6H), 1.11-1.82 (m, 24H), 2.06 (m, 1H), 2.84 (m, 1H), 3.06-3.14 ppm (m, 3H). ¹³C NMR (100 MHZ, CDCl₃, 25°C): δ = 14.1, 14.2, 17.4, 20.2, 22.9, 23, 24.1, 25.1, 25.4, 27.4, 29.4, 33.1, 33.8, 33.8, 34.3, 35.1, 52.9, 53, 55.9, 56.6 ppm. IR (CHCl₃): 769.9, 825.6, 1217, 1259.7, 1377.4, 1456.2, 1738.6, 2858, 2933 cm⁻¹. MS (EI mode) *m*/z %: 154 (6), 139 (2), 136 (2), 125 (4), 111 (64), 97 (38), 81 (56), 68 (68), 55 (100), 51 (8). HRMS (ESI) calcd for $C_{10}H_{18}O[M^+]$ 154.1357, found 154.1358.



(R)-3-tert-butylcyclohex-1-ene 15: prepared from cyclohex-1-enyl-3-bromide 5. Highly volatile product isolated after derivatisation in corresponding epoxides. After treatment with mcpba, 2-tert-butyl-7-oxabicyclo[4.1.0]heptane is isolated as a mixture of diastereoisomeric epoxides with a ratio 1/9. Yield = 80 % (after two steps). ¹H NMR (400 MHZ, CDCl₃, 25°C): $\delta = 0.97$ (m, 8H), 1.25-1.42 (m, 4H), 1.55-1.60 (m, 4H), 1.87 (m, 1H), 2.11 (m, 1H), 3.03 (m, 1H), 3.15-3.20 ppm (m, 1H). 13 C NMR (100 MHZ, CDCl₃, 25°C): $\delta =$ 17.6, 17.7, 17.9, 19.9, 20.3, 22.8, 25.1, 25.2, 27.4, 28.3, 32.7, 38.3, 44.8, 53, 53.1, 53.3, 54.3, 54.6, 55.4 ppm. IR (CHCl₃): 703.7, 751.2, 786.3, 831.2, 842.1, 960.7, 1016.1, 1091.9, 1216.9, 1259.1, 1366.5, 1456.4, 1721.1,

2868.3, 2933 cm⁻¹. MS (EI mode) m/z %:. HRMS (ESI) calcd for C₁₀H₁₈O [M⁺] 154.1352, found 154.1358.

IV) References

- [1] K. Tissot-Croset, D. Polet, S. Gille, C. Hawner, A. Alexakis, Synthesis, 2004, 2586-2590.
- [2] L. Palais, I. S. Mikhel, C. Bournaud, L. Micouin, C. A. Falciola, M. Vuagnoux-d'Augustin, S. Rosset, G. Bernardinelli, A. Alexakis, Angew, Chem. Int. Ed. 2007, 46, 7462-7465.
- [3] S. Okamoto, S. Tominaga, N. Saino, K. Kase, K. Shimoda, J. Organomet. Chem. 2005, 690, 6001-6007.
- [4] C. Djerassi, Chem. Rev. 1948, 43, 271-317.
- [5] B. K. Bettadaiah, K. N. Gurudutt, P. Srinivas, J. Org. Chem. 2003, 68, 2460-2462.
- [6] B. K. Bettadaiah, P. Srinivas, Synthetic Communications, 2003, 33, 3615-3620.
- [7] A. J. Pearson, S. Y. Hsu, J. Org. Chem. 1986, 51, 2505-2511.

V) Spectroscopic datas























75 70 63 60 55 50 45 40 35 30 25 20 15 10 5







Peak results :

Index	Name	Start	Time	End	RTOffset	Quantity	Height	Area	Area
		[Min]	[Min]	[Min]	[Min]	[% Area]	[µV]	[µV.Min]	[%]
1	UNKNOWN	4.40	4.57	4.80	0.00	49.57	446.0	50.1	49.567
2	UNKNOWN	4.80	4.97	5.22	0.00	50.43	422.5	51.0	50.433
Total						100.00	868.5	101.1	100.000





Supplementary Material (ESI) for Chemical Communications This journal is (c) The Royal Society of Chemistry 2009





Supplementary Material (ESI) for Chemical Communications This journal is (c) The Royal Society of Chemistry 2009





peak	R.T.	Start	End]	PK peak	peak	peak	% of
#	min	min	min	5	FY height	area	% max.	total
1	93.896	93.678	94.199		M 484391	50922478	100.00%	43.064%
2	96:311	96.126	96.605		M 337581	35505607	69.72%	30.026%
3	98.944	98.761	99.198		M 132181	12915141	25.36%	10.922%
41	00.351	100.157	100.667		M 188724	18905946	37.13%	15.988%
			Sum	of	corrected	areas:	118249172	2